Top Biotech News From Montgomery County: United Therapeutics Lawsuit, Patent; Gaithersburg, Rocvkille Co's On COVID Drug
1. Gaithersburg’s Novavax Selects FUJIFILM To Manufacture COVID-19
Novavax (Nasdaq: NVAX) has already begun production of its NVX-CoV2373 at a Morrisville, North Carolina plant owned by FUJIFILM Diosynth Biotechnologies. The funding from the deal comes from Novavax’s $1.6 billion award by the federal government as part of Operation Warp Speed (OWS). The manufactured doses will be used in Phase 3 clinical trial that could enroll up to 30,000 patients.
2. Gaithersburg and Rockville Biotechs Partner Up For COVID-19 Vaccine
Gaithersburg-based Altimmune (Nasdaq: ALT) has a single-dose intranasal vaccine candidate for COVID-19 called AdCOVID and it has selected Rockville-based Vigene to do the manufacturing. With recent reports of positive clinical data, Altimmune is planning on moving forward with Phase 1 clinical trial late this year.
3. Silver Spring’s United Therapeutics Wins New Patent, Solidifies Suit Against North Carolina Biotech
First things first, United Therapeutics Corporation (Nasdaq: UTHR) was issued a new patent from the United States Patent and Trademark Office for one of their leading drugs. The patent was related to one of its revenue generating drugs called Tyvaso (treprostinil).
With the new patent United Therapeutics solidifies it lawsuit against Morrisville-N.C.-based Liquidia Technologies, Inc. United Therapeutics claims Liquidia is infringing upon its patent as the company tried to file an inhaled powder form of treprostinil with the Food and Drug Administration (FDA)